Inflammatory Skin Diseases – Pipeline Review, H2 2012

Inflammatory Skin Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Inflammatory Skin Diseases - Pipeline Review, H2 2012', provides an overview of the Inflammatory Skin Diseases therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Skin Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Skin Diseases. 'Inflammatory Skin Diseases - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Inflammatory Skin Diseases.
- A review of the Inflammatory Skin Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Inflammatory Skin Diseases pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Inflammatory Skin Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Inflammatory Skin Diseases pipeline depth and focus of Inflammatory Skin Diseases therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Inflammatory Skin Diseases Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Inflammatory Skin Diseases 7
Inflammatory Skin Diseases Therapeutics under Development by Companies 9
Inflammatory Skin Diseases Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Inflammatory Skin Diseases Therapeutics – Products under Development by Companies 13
Inflammatory Skin Diseases Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Inflammatory Skin Diseases Therapeutics Development 15
Biofrontera AG 15
Warner Chilcott Limited 16
CREABILIS Therapeutics S.r.l. 17
APEIRON Biologics AG 18
Inflammatory Skin Diseases – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
BF-PC/21 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BF-PC/18 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BF-PC/13 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CT327 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
FLAPi - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
WC3027 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
StrataGraft Skin Tissue - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
APN201 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Inflammatory Skin Diseases Therapeutics – Drug Profile Updates 33
Inflammatory Skin Diseases Therapeutics - Dormant Products 35
Inflammatory Skin Diseases – Product Development Milestones 36
Featured News & Press Releases 36
Jul 14, 2010: Perrigo Company Confirms Patent Challenge For Clobetasol Propionate Emulsion Foam 36
Mar 20, 2008: Perrigo company announces launch of clobetasol propionate foam 36
Mar 11, 2008: Perrigo company receives final approval on Clobetasol Propionate foam 36
Sep 01, 2006: Perrigo receives tentative approval for Clobetasol Propionate foam 37
Mar 02, 2006: Medicis Announces FDA Approval of Broader Indication for VANOS 37
Sep 22, 2005: Aqua Pharmaceuticals Licenses Cordran and Monodox for the United States 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Inflammatory Skin Diseases, H2 2012 7
Products under Development for Inflammatory Skin Diseases – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Biofrontera AG, H2 2012 15
Warner Chilcott Limited, H2 2012 16
CREABILIS Therapeutics S.r.l., H2 2012 17
APEIRON Biologics AG, H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Inflammatory Skin Diseases Therapeutics – Drug Profile Updates 33
Inflammatory Skin Diseases Therapeutics – Dormant Products 35

List of Figures
Number of Products under Development for Inflammatory Skin Diseases, H2 2012 7
Products under Development for Inflammatory Skin Diseases – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23